Breast cancer+7
Not recruitingStudy of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment
Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment
- Disease:Breast cancerTriple negative breast cancer+6
- Substances:CapecitabineCarboplatin+2
France- Participants:18–64 years · 65+ years
- Substances:Capecitabine
- Sponsor:GBG Forschungs GmbH










